[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN115052888A - FcγRIIB亲和力增强的抗体Fc区 - Google Patents

FcγRIIB亲和力增强的抗体Fc区 Download PDF

Info

Publication number
CN115052888A
CN115052888A CN202080084609.5A CN202080084609A CN115052888A CN 115052888 A CN115052888 A CN 115052888A CN 202080084609 A CN202080084609 A CN 202080084609A CN 115052888 A CN115052888 A CN 115052888A
Authority
CN
China
Prior art keywords
mutant
antibody
region
mutation
polypeptide fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080084609.5A
Other languages
English (en)
Inventor
李福彬
张燕
张咪
毕艳侠
田世豪
张慧慧
柳淑君
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiaotong University School of Medicine
Original Assignee
Shanghai Jiaotong University School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiaotong University School of Medicine filed Critical Shanghai Jiaotong University School of Medicine
Publication of CN115052888A publication Critical patent/CN115052888A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了一种改造的Fc区，所述Fc区相比于亲本Fc区具有至少一个氨基酸突变，这些改造的Fc区对FcγRIIB的亲和力较亲本Fc区对FcγRIIB的亲和力提高。还公开了包含上述改造的Fc区的抗体，特别是激动型抗体。本发明改造的Fc区对于优化抗体的激动活性具有重要用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080084609.5A 2019-12-03 2020-12-03 FcγRIIB亲和力增强的抗体Fc区 Pending CN115052888A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911223227 2019-12-03
CN2019112232271 2019-12-03
PCT/CN2020/133685 WO2021110110A1 (zh) 2019-12-03 2020-12-03 FcγRIIB亲和力增强的抗体Fc区

Publications (1)

Publication Number Publication Date
CN115052888A true CN115052888A (zh) 2022-09-13

Family

ID=76222463

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080084609.5A Pending CN115052888A (zh) 2019-12-03 2020-12-03 FcγRIIB亲和力增强的抗体Fc区

Country Status (10)

Country Link
US (1) US20230220042A1 (zh)
EP (1) EP4071167A4 (zh)
JP (1) JP2023507922A (zh)
KR (1) KR20220121822A (zh)
CN (1) CN115052888A (zh)
AU (1) AU2020396825A1 (zh)
BR (1) BR112022010757A2 (zh)
CA (1) CA3160574A1 (zh)
MX (1) MX2022006670A (zh)
WO (1) WO2021110110A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240294646A1 (en) * 2020-05-20 2024-09-05 Zymeworks Bc Inc. HETERODIMERIC Fc VARIANTS SELECTIVE FOR Fc GAMMA RIIB
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0981618T4 (da) 1997-05-15 2011-11-21 Genentech Inc Anti-Apo-2-antistof
AU7830398A (en) 1997-06-11 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
AU2338299A (en) 1998-01-26 1999-08-09 Genentech Inc. Antibodies to death receptor 4 (dr4) and uses thereof
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
PL2471813T3 (pl) * 2004-07-15 2015-09-30 Xencor Inc Zoptymalizowane warianty Fc
US7700099B2 (en) * 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
AU2008207898B2 (en) * 2007-01-23 2012-05-03 Xencor, Inc Optimized CD40 antibodies and methods of using the same
EP3392273A1 (en) * 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
US9296815B2 (en) * 2010-03-29 2016-03-29 Zymeworks Inc. Antibodies with enhanced or suppressed effector function
BR112013031198B1 (pt) * 2011-06-06 2020-10-20 Novo Nordisk A/S anticorpo de ligação a c5ar e seu uso
RS63897B1 (sr) * 2015-05-29 2023-02-28 Bristol Myers Squibb Co Antitela protiv ox40 i njihova primena

Also Published As

Publication number Publication date
MX2022006670A (es) 2023-03-17
WO2021110110A1 (zh) 2021-06-10
KR20220121822A (ko) 2022-09-01
US20230220042A1 (en) 2023-07-13
EP4071167A1 (en) 2022-10-12
EP4071167A4 (en) 2024-03-06
CA3160574A1 (en) 2021-06-10
JP2023507922A (ja) 2023-02-28
AU2020396825A1 (en) 2022-07-21
BR112022010757A2 (pt) 2022-08-16

Similar Documents

Publication Publication Date Title
EP3464367B1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
EP3259597B1 (en) Pvrig polypeptides and methods of treatment
US20190211113A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
CN107474136B (zh) 增强激动型抗体活性的抗体重链恒定区序列
TW201930359A (zh) 抗tigit抗體及其作為治療和診斷的用途
CN113597433A (zh) Gprc5d嵌合抗原受体以及表达这些受体的细胞
TW201920653A (zh) 調節細胞表達的生物活性之結合分子
TW202342540A (zh) 用於癌之治療的細胞傷害誘導治療劑
CN106632681A (zh) 抗egfr 和抗cd3双特异抗体及其应用
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
CN110551221A (zh) 一种双特异性抗体及其制备方法与应用
JP7115758B2 (ja) Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ
US20220220215A1 (en) Binding molecules
US20240343811A1 (en) Cd16 antibody and use thereof
CN117106099A (zh) 一种抗dll3嵌合抗原受体及其用途
CN104829725A (zh) 一种双特异性抗体cd133×cd3的构建及应用
CN115052888A (zh) FcγRIIB亲和力增强的抗体Fc区
US20210380691A1 (en) Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN116390933A (zh) 治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法
CN112592404B (zh) 抗体活性改造及其筛选方法
CA3237992A1 (en) Truncated taci polypeptide and fusion protein and use thereof
CN114773467B (zh) 抗SIRPα抗体或其抗原结合片段及应用
CN118355024A (zh) 包含il-21r突变蛋白的免疫细胞因子
CN117203341A (zh) 用于治疗或预防炎症性疾病的抗人pd-1激动剂抗体和含有其的药物组合物
CN117164719A (zh) 靶向SIRPα和PD-L1的双特异性抗体或其抗原结合片段及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080742

Country of ref document: HK